Résultats de recherchePour la revue "Harm Reduction Journal" :  8 articles trouvés.

Addictions aux opiacés  Article original (Abstract) | Publié le 16-02-2024
  Bertin Célian et al. | Harm Reduction Journal 2023; 20(1): 130
Opioid use disorder is a diagnosis introduced in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders [1], combining the separate diagnoses of dependence and abuse from the previous edition [2, 3]. The diagnosis applies to anyone who maintains their opioid use for more than 12 months, despite negative consequences for themselves and those around them [4]. The initiation...

Addictions aux opiacés  Article original (Abstract) | Publié le 21-06-2023
  Jaffe Kaitlyn et al. | Harm Reduction Journal 2023; 20(1): 51
In North America, over 100,000 people have died from drug poisoning in the past year, due to the increasingly toxic drug supply [1, 2]. Compounding this, the COVID-19 pandemic increased overdose risks for people who use drugs (PWUD), in part through reductions in the availability or access to essential health and treatment services [3–5]. Among those essential services, opioid agonist treatment...

Addictions aux opiacés  Article original (Abstract) | Publié le 03-04-2023
  Henderson Rita et al. | Harm Reduction Journal 2023; 20(1): 34
This realist review examines international literature focused on interventions for opioid dependence in Indigenous communities in countries with similar healthcare systems and colonial histories to Canada to discover activities or strategies that might be relevant in our context. The term “intervention” is commonly used in Canada to refer to programs or policies designed to respond to community-...

Addictions aux opiacés  Article original (Abstract) | Publié le 04-03-2023
  Neale Joanne et al. | Harm Reduction Journal 2019; 16(1): 25
Opioid agonist therapy (OAT) is a well-evidenced treatment for opioid use disorder that involves the prescription of pharmaceutical opioids such as the agonist (methadone) and the partial agonist (buprenorphine) [1, 2]. Historically, OAT medications have nearly always been prescribed for daily consumption in liquid/linctus or tablet/film form. In recent years, however, treatment options have started...

Addictions aux opiacés  Article original (Abstract) | Publié le 12-12-2022
  Fitzpatrick Thomas et al. | Harm Reduction Journal 2022; 19(1): 103
People who use heroin (PWUH) have increased morbidity and mortality compared to the general population [1]. A syndemic of opioid overdose, human immunodeficiency virus (HIV), hepatitis C virus (HCV), skin and soft tissue infections (SSTI), and infective endocarditis accounts for many of the poor health outcomes among PWUH [2–5]. Heroin can be consumed in several ways, including injection and...

Addictions aux opiacés  Article original (Abstract) | Publié le 15-02-2022
  Samsó Jofra Laura et al. | Harm Reduction Journal 2022; 19(1): 7
Opioid agonist treatments (OATs) reduce injection-related mortality and morbidity [1–3], all-cause and overdose mortality [4–6], and improve quality of life [7, 8] among people with opioid use disorder. In fact, the safety, efficacy and effectiveness of the two most commonly used OAT medications (i.e., methadone and buprenorphine) have been widely researched and proved [9–12]. Despite...

798 articles actuellement disponibles

Rechercher

Besoin d'aide ?
Recherche avancée
Recherche par revues
Sélectionnez l'initiale de la revue recherchée
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0-9
Recherche par rubriques